Home › News › Clinical Trials

Merck Ends Phase 3 Development of Investigational BTK Inhibitor Nemtabrutinib

Merck Ends Phase 3 Development of Investigational BTK Inhibitor Nemtabrutinib

Merck, known as MSD outside the United States and Canada, has discontinued the clinical development programme for nemtabrutinib (MK-1026), an investigational oral, non-covalent Bruton's Tyrosine Kinase (BTK) inhibitor being evaluated for Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Leukaemia (SLL) and other haematological malignancies.

The decision follows a review of the Phase 3 BELLWAVE-011 trial by an external Data Monitoring Committee (eDMC), which indicated that the potential benefits of nemtabrutinib might not outweigh the risks in the study. Merck subsequently conducted its own comprehensive review of the available data and decided to discontinue the broader BELLWAVE clinical development programme.

The discontinuation includes the Phase 3 BELLWAVE-011, BELLWAVE-008 and BELLWAVE-010 studies. The programme was designed to evaluate nemtabrutinib in patients with CLL, SLL and other blood cancers.

Merck is notifying investigators involved in the clinical trials and has advised patients to consult their study teams and physicians regarding further treatment options and next steps. The company stated that data analyses from the trials are ongoing and that the findings will be shared with the scientific community.

Commenting on the decision, Dr. Marjorie Green, Senior Vice President and Head of Global Oncology Clinical Development at Merck Research Laboratories, said the company had decided to discontinue nemtabrutinib development across the clinical programme following a comprehensive analysis of the BELLWAVE-011 data. She also acknowledged the contributions of patients, caregivers and investigators involved in the studies and reaffirmed Merck's focus on advancing its haematology pipeline.

More news about: clinical trials | Published by News Bureau | November - 20 - 2026

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members